Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 4/2010

01.04.2010 | Short Communication

Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells

verfasst von: Zoran Popmihajlov, Fabio R. Santori, Daniel Gebreselassie, Anthony D. Sandler, Stanislav Vukmanovic

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

High avidity for antigen and diversity of T cell receptor (TCR) repertoire are essential for effective immunity against cancer. We have previously created a transgenic mouse strain with increased TCR avidity in a diverse T cell population. In this report, we show that strong alloreactive responses of transgenic T cells against targets with low MHC class I expression can be used for effective adoptive transfer of tumor immunity in vivo. Alloreactive transgenic T cells could be an effective therapeutic approach counteracting tumor evasion of the immune system.
Literatur
1.
Zurück zum Zitat Rosenberg SA et al (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299–308CrossRefPubMed Rosenberg SA et al (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299–308CrossRefPubMed
2.
Zurück zum Zitat Schumacher TN, Restifo NP (2009) Adoptive T cell therapy of cancer. Curr Opin Immunol 21(2):187–189CrossRefPubMed Schumacher TN, Restifo NP (2009) Adoptive T cell therapy of cancer. Curr Opin Immunol 21(2):187–189CrossRefPubMed
3.
Zurück zum Zitat Zeh HJI et al (1999) High avidity CTLs for two self antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162:989–994PubMed Zeh HJI et al (1999) High avidity CTLs for two self antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162:989–994PubMed
4.
Zurück zum Zitat Van den Eynde BJ, Boon T (1997) Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27(2):81–86CrossRefPubMed Van den Eynde BJ, Boon T (1997) Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27(2):81–86CrossRefPubMed
5.
Zurück zum Zitat Bouneaud C, Kourilsky P, Bousso P (2000) Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13:829–840CrossRefPubMed Bouneaud C, Kourilsky P, Bousso P (2000) Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13:829–840CrossRefPubMed
6.
Zurück zum Zitat Stauss HJ (1999) Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 20:180–183CrossRefPubMed Stauss HJ (1999) Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 20:180–183CrossRefPubMed
7.
Zurück zum Zitat Stauss HJ et al (2004) Exploiting alloreactivity for tumour immunotherapy. Vox Sang 87(Suppl 2):227–229CrossRefPubMed Stauss HJ et al (2004) Exploiting alloreactivity for tumour immunotherapy. Vox Sang 87(Suppl 2):227–229CrossRefPubMed
8.
Zurück zum Zitat Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12):4371–4383CrossRefPubMed Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12):4371–4383CrossRefPubMed
9.
Zurück zum Zitat Childs R et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343(11):750–758CrossRefPubMed Childs R et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343(11):750–758CrossRefPubMed
10.
Zurück zum Zitat Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3(11):999–1005CrossRefPubMed Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3(11):999–1005CrossRefPubMed
11.
Zurück zum Zitat Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227–236CrossRefPubMed Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227–236CrossRefPubMed
12.
Zurück zum Zitat Garcia-Lora A et al (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106(4):521–527CrossRefPubMed Garcia-Lora A et al (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106(4):521–527CrossRefPubMed
13.
Zurück zum Zitat Vago L et al (2009) Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 361(5):478–488CrossRefPubMed Vago L et al (2009) Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 361(5):478–488CrossRefPubMed
14.
Zurück zum Zitat van Hall T et al (2006) Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12(4):417–424CrossRefPubMed van Hall T et al (2006) Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12(4):417–424CrossRefPubMed
15.
Zurück zum Zitat Santori FR et al (2007) TCRβ chain that forms peptide-independent alloreactive TCR transfers reduced reactivity with irrelevant peptide/MHC complex. J Immunol 178:6109–6114PubMed Santori FR et al (2007) TCRβ chain that forms peptide-independent alloreactive TCR transfers reduced reactivity with irrelevant peptide/MHC complex. J Immunol 178:6109–6114PubMed
16.
Zurück zum Zitat Stojakovic M et al (2008) Adaptable TCR avidity thresholds for negative selection. J Immunol 181:6770–6778PubMed Stojakovic M et al (2008) Adaptable TCR avidity thresholds for negative selection. J Immunol 181:6770–6778PubMed
17.
Zurück zum Zitat Nesic D et al (2002) Factors influencing the patterns of T lymphocyte allorecognition. Transplantation 73:797–803CrossRefPubMed Nesic D et al (2002) Factors influencing the patterns of T lymphocyte allorecognition. Transplantation 73:797–803CrossRefPubMed
18.
Zurück zum Zitat Gebreselassie D, Spiegel H, Vukmanovic S (2006) Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum Immunol 67:894–906CrossRefPubMed Gebreselassie D, Spiegel H, Vukmanovic S (2006) Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum Immunol 67:894–906CrossRefPubMed
19.
Zurück zum Zitat Balendiran GK et al (1997) The three-dimensional structure of an H-2Ld-peptide complex explains the unique interaction of Ld with beta-2 microglobulin and peptide. Proc Natl Acad Sci USA 94(13):6880–6885CrossRefPubMed Balendiran GK et al (1997) The three-dimensional structure of an H-2Ld-peptide complex explains the unique interaction of Ld with beta-2 microglobulin and peptide. Proc Natl Acad Sci USA 94(13):6880–6885CrossRefPubMed
20.
Zurück zum Zitat Udaka K et al (1993) A ubiquitous protein is the source of naturally occurring peptides that are recognized by a CD8+ T-cell clone. Proc Natl Acad Sci USA 90:11272–11276CrossRefPubMed Udaka K et al (1993) A ubiquitous protein is the source of naturally occurring peptides that are recognized by a CD8+ T-cell clone. Proc Natl Acad Sci USA 90:11272–11276CrossRefPubMed
21.
Zurück zum Zitat Uenaka A et al (1994) Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med 180:1599–1607CrossRefPubMed Uenaka A et al (1994) Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med 180:1599–1607CrossRefPubMed
22.
Zurück zum Zitat Sabatino DE et al (2005) Identification of mouse AAV capsid-specific CD8 + T cell epitopes. Mol Ther 12(6):1023–1033CrossRefPubMed Sabatino DE et al (2005) Identification of mouse AAV capsid-specific CD8 + T cell epitopes. Mol Ther 12(6):1023–1033CrossRefPubMed
23.
Zurück zum Zitat Kearney ER et al (1994) Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1(4):327–339CrossRefPubMed Kearney ER et al (1994) Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1(4):327–339CrossRefPubMed
24.
Zurück zum Zitat Kruger T et al (2005) Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 54:826–836CrossRefPubMed Kruger T et al (2005) Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 54:826–836CrossRefPubMed
25.
Zurück zum Zitat Sandberg JK, Karre K, Glas R (1999) Recognition of the major histocompatibility complex restriction element modulates CD8+ T cell specificity and compensates for loss of T cell receptor contacts with the specific peptide. J Exp Med 189:883–893CrossRefPubMed Sandberg JK, Karre K, Glas R (1999) Recognition of the major histocompatibility complex restriction element modulates CD8+ T cell specificity and compensates for loss of T cell receptor contacts with the specific peptide. J Exp Med 189:883–893CrossRefPubMed
Metadaten
Titel
Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells
verfasst von
Zoran Popmihajlov
Fabio R. Santori
Daniel Gebreselassie
Anthony D. Sandler
Stanislav Vukmanovic
Publikationsdatum
01.04.2010
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 4/2010
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0805-5

Weitere Artikel der Ausgabe 4/2010

Cancer Immunology, Immunotherapy 4/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.